Severe pemphigoid nodularis successfully treated with dupilumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe pemphigoid nodularis successfully treated with dupilumab

Published:2022-07-31 Issue:9 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Jendoubi Fatma¹^ORCID,Bost Chloe²,Tournier Emilie³,Paul Carle¹,Konstantinou Maria Polina¹^ORCID

Affiliation:

1. Dermatology Department University Hospital of Toulouse and Paul Sabatier University Toulouse France

2. Immunology Laboratory University Hospital of Toulouse Toulouse France

3. Pathology Department University Institute of Cancer Toulouse Oncopole and University Hospital of Toulouse Toulouse France

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15727

Reference9 articles.

1. Pemphigoid nodularis (non-bullous): a clinicopathological study of five cases

2. Nonbullous pemphigoid: a systematic review;Lamberts A;J Am Acad Dermatol

3. Skin-Homing Interleukin-4 and -13-Producing Cells Contribute to Bullous Pemphigoid: Remission of Disease is Associated with Increased Frequency of Interleukin-10-Producing Cells

4. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review;Journal of Clinical Medicine;2024-08-16

2. Hickam versus Ockham: atopic dermatitis and bullous pemphigoid or pemphigoid nodularis? Dupilumab solves the problem;Italian Journal of Dermatology and Venereology;2024-05

3. Evaluation of Dupilumab in Patients With Bullous Pemphigoid;JAMA Dermatology;2023-09-01

4. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study;Frontiers in Immunology;2023-07-20

5. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study;Immunity, Inflammation and Disease;2023-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3